The effect and molecular action of curcumin in FDA-approved clinical drug-treated human bladder cancer cells

• Main Authors: Ya-Wen Fan, 范雅雯
• Other Authors: Chun-Li Su
• Format: Others
• Language: zh-TW
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/63474138092702105330

碩士 === 國立臺灣師範大學 === 人類發展與家庭學系 === 102 === Bladder cancer is the ninth most common cancer worldwide and the fourteenth most diagnosed malignancy in Taiwan (2013). Gemcitabine plus cisplatin (GC) treatment is prefered for nowadays treatment. For patients with impaired renal function, gemcitabine plus carboplatin (GCa) treatment is recommended. Overexpressions of Aurora A kinase and epidermal growth factor (EGF) were observed in bladder cancer cells. Our previously data demonstrate that curcumin significantly inhibited Aurora A gene expression, in part caused failure of various mitotic events and G2/M arrest of human bladder cancer cells. In this study, human bladder cancer T24 cells were treated with the existing chemotherapy (GC or GCa) in the presence and absence of curcumin. Addition of curcumin not only produced synergism using combination index analysis, but also raised the percentages of phases in sub-G1 (apoptosis rate) and G2/M using flow cytometry. Combinatio of cucurmin induced autophagy. Decreasing of phospho-Aurora A, p62, Beclin-1, phospho-PI3K, phospho-p70s6k, Atg12-Atg5 and increasing of LC3-II, phospho-mTOR, phospho-AKT, phospho-MEK, phospho-ERK were observed. Taken together, clinical drugs combined with curcumin not only inhibited activity of aurora a, but also promoted apoptosis and autophagy in T24 cells.